TRVI snapshot historyBase and published updates, newest first.
EventPriceVS BASEVS PRIORVol. ratioRSI52w pos.EMA trend
S15 · 17:40$18.39-3.01%+0.47%
S15 · 10:54$18.30-3.48%-1.05%
S15 · 08:36$18.50-2.43%0.00%
S14 · 18:04$18.50-2.43%-0.79%
S14 · 11:06$18.65-1.64%0.00%
Aftermarket · S14 · 08:42$18.65-1.64%0.00%
S13 · 17:40$18.65-1.64%-0.85%
S13 · 10:53$18.81-0.79%+0.32%
S13 · 08:37$18.75-1.11%0.00%
Base · 12:41$18.960.00%0.00%2.41x53.7393.92%18.02 > 17.48 > 16.36
Raw TryFinally

TRVITrevi Therapeutics, Inc.

NASDAQ

Healthcare · Market cap $2.7B

+9.01% · 2.41x volume · 18.02 > 17.48 > 16.36

Panel thesis: TRVI is presented as a Raw Try: the market trajectory is constructive enough to monitor, but the missing verified catalyst prevents a Try of the Day designation.

Company context

Trevi Therapeutics, Inc. is a Nasdaq-listed healthcare company. The point-in-time scan did not include a verified company profile beyond its listing and sector, so this company overview remains deliberately limited.

Price record

Observed price path

Base price $18.96 · Updated with each published update.
TRVI observed price path
Structural context

Price channel and relative performance

Six-month price channel · 20-session excess versus sector.
TRVI six-month price channel and 20-session relative performance versus sector

Public scanner fields captured at the base snapshot; deeper research inputs remain private.

Snapshot

What was captured at the base

Base price$18.96
Change on day+9.01%
Volume vs 3-month average2.41x 3-month average
RSI (14)53.73

Structure

How price is behaving

Price vs session VWAPBelow VWAP · $19.21 · -1.30% from VWAP
EMA trend18.02 > 17.48 > 16.36
52-week position93.92% of 52-week high
ATR extension from EMA21Healthy · 1.11 ATR from EMA21
Session range position58% of session range

Risk and context

What may change the read

Relative strengthIdiosyncratic · +9.97% vs QQQ
Volume percentile95.20th percentile · Exceptional
Gap at open+1.30%
Earnings riskClear
Short interest10.85%
Days to cover6.33
CatalystManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday

Base framework for context and outcome tracking. These are not trading instructions.

Base$18.96
Downside$17.00
Upside 1$20.92
Upside 2$22.87

Tracking results

+1 sessions
Observed price$16.77CoverageComplete-11.55% from $18.96 baseJul 20, 2026 · 17:04 NASDAQAdvance +2.16% · Drawdown -12.34%
+5 sessions
Observed price$17.53CoverageComplete-7.52% from $18.96 baseJul 24, 2026 · 17:47 NASDAQAdvance +2.16% · Drawdown -12.34%
+10 sessions
Observed price$18.25CoverageComplete-3.74% from $18.96 baseJul 31, 2026 · 17:32 NASDAQAdvance +2.16% · Drawdown -12.34%
+15 sessions
Observed price$18.51CoverageComplete-2.37% from $18.96 baseAug 7, 2026 · 17:31 NASDAQAdvance +2.16% · Drawdown -12.34%

Observed daily-bar ranges are retrospective measurements, not targets, stops, or trading instructions.

Five analytical lenses

Tryding Review

Adversarial review

Five AI analytical agents reading the same evidence; disagreement stays visible.

Elena Vartanyanindependent statistical auditor
“The trajectory supports observation, not a calibrated directional claim.”

A same-day leader is not proven to have repeatable forward advantage.

Marcus Feldinformation, fundamentals and catalyst analyst
“No verified issuer-relevant mechanism explains the move.”

Price action cannot replace attributable information.

Follow-up

Timeline

Session 15 · Aug 7, 2026 · 17:40 NASDAQ
Terminal closure💬$18.39-3.01% base+0.47% prior

TRVI closes its 15-session tracking window at $18.51 against the $18.96 scanner reference, a complete -2.37% outcome; the fresh after-market quote is also $18.51. The original Raw Try thesis correctly identified a constructive tape above VWAP, but it also named decelerating participation and the absence of a verified catalyst as decisive caveats. The subsequent recovery attempts never produced durable follow-through, so the Mesa closes the episode as an unresolved conditional thesis rather than a confirmed continuation, and it is no longer followed.

Session 12 · Aug 4, 2026 · 17:41 NASDAQ
Relevant update💬$18.75-1.11% base+2.69% prior

TRVI recovered 2.27 points in tracked return to -1.11%, with the latest quote at $18.75 up 4.75% on 1.04x participation. The rising EMA stack supports a repair attempt, but neutral flow, a 2.43-point sector-relative headwind and no current VWAP capture leave follow-through unconfirmed.

Session 6 · Jul 27, 2026 · 18:31 NASDAQ
Relevant update💬$18.12-4.43% base0.00% prior

TRVI recovered from -11.08% to -8.11%, moving from $17.54 to $18.12, but the post-reconstitution relief thesis still needs a higher low and tighter base with visible demand. No fresh issuer-specific event is available, so price structure remains the next confirmation rather than a new explanation.

Session 0 · Jul 17, 2026 · 13:31 NASDAQ
Original publication💬$18.96 · +9.01% change on day

The scanner reference was $18.96 with a $17.00 stop and targets at $20.92 and $22.87. The structure remains constructive while price holds VWAP and the upper intraday range; a sustained loss of either condition would invalidate the follow-through case.

Other candidates

Other candidates

Alternatives retained from the source publication.

LCID
Alternative

The gain cleared the radar gate but relative volume was only marginally above the threshold and the broader evidence stack was weaker.

Open LCID chart on TradingView

History

  • Trevi Therapeutics was incorporated under Delaware law on March 17, 2011.
  • The company is headquartered in New Haven, Connecticut.
  • Trevi is a clinical-stage biopharmaceutical company.
  • Its lead investigational therapy is Haduvio, an oral extended-release formulation of nalbuphine.
  • The company focuses its development work on chronic-cough disorders.

Curiosities

  • Haduvio is being studied for chronic cough associated with idiopathic pulmonary fibrosis.
  • The development scope also includes non-IPF interstitial lung disease and refractory chronic cough.
  • The company describes Haduvio as acting on the cough-reflex arc through a kappa-agonist and mu-antagonist mechanism.
  • Nalbuphine has been approved and marketed as an injectable pain medicine for decades in the United States and Europe.
  • MarketScreener classifies Trevi Therapeutics as a clinical-stage biopharmaceutical company.

Profile sources